共 50 条
- [21] HIGH-RISK RECTAL CANCER NEO-ADJUVANT CAPECITABINE AND OXALIPLATIN BEFORE RADIOTHERAPY WITH CONCOMITANT CAPECITABINE AND RADICAL SURGERY LOCOREGIONAL RESPONSESTRAHLENTHERAPIE UND ONKOLOGIE, 2010, 186 (12) : 724 - 725Brodmann, S.Bateman, A. C.Bateman, A.
- [22] Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with 177Lu-PSMA-I&T in Metastatic Castration-resistant Prostate CancerEUROPEAN UROLOGY, 2019, 75 (06) : 920 - 926Heck, Matthias M.Tauber, RobertSchwaiger, SebastianRetz, MargittaD'Alessandria, CalogeroMaurer, TobiasGafita, AndreiWester, Hans-JuergenGschwend, Juergen E.Weber, Wolfgang A.Schwaiger, MarkusKnorr, KarinaEiber, Matthias
- [23] RADIOLIGAND THERAPY WITH 177LU-PSMA-I&T IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: ONCOLOGICAL OUTCOMES AND TOXICITY PROFILEJOURNAL OF UROLOGY, 2023, 209 : E125 - E126Demirkol, Mehmet OnurEsen, BarisSen, MelisUcar, BurcuKurtuldu, SevgilayMandel, Nil MolinasBavbek, SevilFalay, OkanTilki, DeryaEsen, Tarik
- [24] Adjuvant weekly docetaxel for high-risk prostate cancer patients after radical prostatectomyJOURNAL OF UROLOGY, 2006, 175 (04): : 512 - 512Kibel, ASKattan, MWPicus, JDreicer, RKlein, EAWilding, GJarrard, DFRoth, BCookson, MSPettylak, DPChatta, GNelson, JBBeer, TMDipaola, RPartin, AIRosenbaum, EGarrett, ESugar, EEisenberger, M
- [25] Adjuvant weekly docetaxel for high-risk prostate cancer patients after Radical ProstatectomyJOURNAL OF UROLOGY, 2005, 173 (04): : 222 - 222Kibel, ASPicus, JCookson, MSRoth, BJarrard, DFWilding, GKlein, EADreicer, RNelson, JBChatta, GBenson, MCPetrylak, DPDiPaola, RBeer, TMDiamond, JPartin, AWEisenberger, MA
- [26] Pilot trial of adjuvant paclitaxel (T) and estramustine phosphate (EMP) for high-risk prostate cancer patients after radical prostatectomy (RP).JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 446S - 446SLubiniecki, GMMalkowicz, SBHendricks, MBearn-Miranda, Lvan Arsdalen, KWein, AVaughn, DJ
- [27] FEASIBILITY OF RADICAL PROSTATECTOMY FOLLOWING NEOADJUVANT IXABEPILONE FOR HIGH-RISK PROSTATE CANCER: A PHASE II CLINICAL TRIALJOURNAL OF UROLOGY, 2013, 189 (04): : E314 - E315Maddox, MichaelLayton, JodiTaber, AngelaMega, AnthonyRenzulli, Joseph, II
- [28] Costs of radium-223 and the pharmacy preparation 177Lu-PSMA-I&T for metastatic castration-resistant prostate cancer in Dutch hospitalsJOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 366 - 375Quist, S. W.Paulissen, J. H. J.Wyndaele, D. N. J.Nagarajah, J.Freriks, R. D.
- [29] Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancerCLINICAL CANCER RESEARCH, 2005, 11 (14) : 5233 - 5240Febbo, PGRichie, JPGeorge, DJLoda, MManola, JShankar, SBarnes, ASTempany, CCatalona, WKantoff, PWOh, WK
- [30] Metastatic Disease Response and Patterns of Recurrence in Men with High-Risk Prostate Cancer after Neo-Adjuvant Chemohormonal Therapy and Radical Prostatectomy utilizing PSMA-Targeted 18F-DCFPyL PET/CTJOURNAL OF NUCLEAR MEDICINE, 2021, 62Lovrec, PetraBelson, PatrickWells, ShaneKyriakopoulos, ChristosHuang, WeiBeebe, DavidLang, JoshuaJarrard, DavidCho, Steve